Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
30.00
+0.54 (1.83%)
Jun 15, 2026, 10:09 AM EDT - Market open
Agios Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 113.6 | 89.13 | 76.25 | 88.21 | 139.26 | 203.13 |
Short-Term Investments | 623.44 | 765.3 | 817.46 | 688.72 | 643.86 | 816.89 |
Cash & Short-Term Investments | 737.04 | 854.43 | 893.71 | 776.93 | 783.12 | 1,020 |
Cash Growth | -17.50% | -4.40% | 15.03% | -0.79% | -23.23% | 78.04% |
Accounts Receivable | 16.13 | 10.58 | 4.11 | 2.81 | 2.21 | - |
Other Receivables | - | - | - | - | - | 4.38 |
Total Trade Receivables | 16.13 | 10.58 | 4.11 | 2.81 | 2.21 | 4.38 |
Inventory | 35.09 | 32.92 | 27.62 | 19.08 | 8.49 | - |
Other Current Assets | 46.59 | 44.13 | 40.17 | 35.02 | 38.96 | 39.84 |
Total Current Assets | 834.84 | 942.05 | 965.6 | 833.84 | 832.77 | 1,064 |
Net Property, Plant & Equipment | 37.76 | 41.23 | 54.55 | 69.79 | 88.12 | 104.23 |
Long-Term Investments | 308.45 | 310.01 | 638.32 | 29.44 | 313.87 | 266.38 |
Other Long-Term Assets | 3.93 | 3.93 | 4.72 | 4.06 | 3.96 | 2.9 |
Total Assets | 1,185 | 1,297 | 1,663 | 937.12 | 1,239 | 1,438 |
Accounts Payable | 13.75 | 18.36 | 16.64 | 9.78 | 18.62 | 16.7 |
Accrued Expenses | 26.29 | 45.46 | 46.86 | 43.17 | 30.35 | 31.97 |
Current Portion of Leases | 18.81 | 18.39 | 16.78 | 15.01 | 13.66 | 11.16 |
Other Current Liabilities | - | - | 0.87 | - | - | - |
Total Current Liabilities | 58.85 | 82.21 | 81.16 | 67.96 | 62.63 | 59.83 |
Long-Term Leases | 16.94 | 21.82 | 40.21 | 56.99 | 72 | 85.94 |
Other Long-Term Liabilities | 0.09 | 0.09 | 0.88 | 1.16 | 3.28 | - |
Total Long-Term Liabilities | 17.03 | 21.91 | 41.09 | 58.14 | 75.28 | 85.94 |
Total Liabilities | 75.88 | 104.11 | 122.24 | 126.1 | 137.9 | 145.76 |
Common Stock | 0.08 | 0.08 | 0.07 | 0.07 | 0 | 0.07 |
Treasury Stock | -802.49 | -802.49 | -802.49 | -802.49 | -802.49 | -802.49 |
Additional Paid-in Capital | 2,573 | 2,555 | 2,494 | 2,437 | 2,386 | 2,334 |
Accumulated Other Comprehensive Income | -0.31 | 2.19 | -1.52 | -0.44 | -12.54 | -1.2 |
Retained Earnings | -660.82 | -561.71 | -148.92 | -822.65 | -470.56 | -238.76 |
Shareholders' Equity | 1,109 | 1,193 | 1,541 | 811.02 | 1,101 | 1,292 |
Total Liabilities & Equity | 1,185 | 1,297 | 1,663 | 937.12 | 1,239 | 1,438 |
Total Debt | 35.75 | 40.21 | 56.99 | 72 | 85.66 | 97.09 |
Net Cash (Debt) | 701.29 | 814.22 | 836.72 | 704.93 | 697.46 | 922.92 |
Net Cash Growth | -13.87% | -2.69% | 18.70% | 1.07% | -24.43% | 97.32% |
Net Cash Per Share | 12.03 | 14.04 | 14.45 | 12.67 | 12.73 | 15.27 |
Book Value | 1,109 | 1,193 | 1,541 | 811.02 | 1,101 | 1,292 |
Book Value Per Share | 19.02 | 20.58 | 26.62 | 14.57 | 20.09 | 21.37 |
Tangible Book Value | 1,109 | 1,193 | 1,541 | 811.02 | 1,101 | 1,292 |
Tangible Book Value Per Share | 19.02 | 20.58 | 26.62 | 14.57 | 20.09 | 21.37 |